Is there a role for macrolides in severe asthma?

Current Opinion in Pulmonary Medicine

Volumn 20, Issue 1, 2014, Pages 95-102

  Brusselle, Guy G ^a,b   Joos, Guy ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

asthma; asthma phenotypes; azithromycin; macrolides; neutrophilic airway inflammation; severe asthma

Indexed keywords

AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CLARITHROMYCIN; CORTICOSTEROID; ERYTHROMYCIN; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; LEUKOCYTE ELASTASE; MACROLIDE; NITRIC OXIDE;

ADD ON THERAPY; ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; BRONCHUS BIOPSY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RHINOSINUSITIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL MOTILITY; HAEMOPHILUS INFECTION; HEARING IMPAIRMENT; HUMAN; IMMUNOMODULATION; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; NEUTROPHILIA; NONHUMAN; NOSE POLYP; OTOTOXICITY; PLEIOTROPY; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; SPUTUM ANALYSIS; TREATMENT RESPONSE;

ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MACROLIDES; PHENOTYPE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84890114841     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000017     Document Type: Review

References (55)

1. Wenzel SE. Asthma: Defining of the persistent adult phenotypes. Lancet 2006; 368:804-813
2. Wenzel SE. Asthma phenotypes: The evolution from clinical to molecular approaches. Nat Med 2012; 18:716-725
3. Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med 2010; 181:315-323
4. Hammad H, Lambrecht BN. Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses. Allergy 2011; 66:579-587
5. Lambrecht BN, Hammad H. The role of dendritic and epithelial cells as master regulators of allergic airway inflammation. Lancet 2010; 376:835-843
6. Crosbie PAJ, Woodhead MA. Long-Term macrolide therapy in chronic inflammatory airway diseases. Eur Respir J 2009; 33:171-181
7. Good JTJ, Rollins DR, Martin RJ. Macrolides in the treatment of asthma. Curr Opin Pulm Med 2012; 18:76-84
8. Fitzgerald JE, King TE Jr, Lynch DA, et al. Diffuse panbronchiolitis in the United States. Am J Respir Crit Care Med 1996; 154:497-503
9. Koyama H, Geddes DM. Erythromycin and diffuse panbronchiolitis. Thorax 1997; 52:915-918
10. Kadota J, Mukae H, Ishii H, et al. Long-Term efficacy and safety of clarithromycin treatment in patients with diffuse panbronchiolitis. Respir Med 2003; 97:844-850
11. Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-984
12. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. JAMA 2003; 290:1749-1756
13. Saiman L, Mayer-Hamblett N, Campbell P, et al. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172:1008-1012
14. Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial. JAMA 2010; 303:1707-1715
15. Wong C, Jayaram L, Karalus N, et al. Azithromycin for prevention of exacerbations in noncystic fibrosis bronchiectasis (EMBRACE): A randomised, double-blind, placebo-controlled trial. Lancet 2012; 380:660-667
16. Altenburg J, de Graaff CS, Stienstra Y, et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: The BAT randomized controlled trial. JAMA 2013; 309:1251-1259
17. Serisier DJ, Martin ML, McGuckin MA, et al. Effect of long-Term, low-Dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: The BLESS randomized controlled trial. JAMA 2013; 309:1260-1267
18. Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-Term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178:1139-1147
19. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365:689-698
20. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359:2355-2365
21. Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37:164-172
22. Verleden GM, Vanaudenaerde BM, Dupont LJ, et al. Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2006; 174:566-570
23. Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic airways. PLoS One 2010; 5:e8578
24. McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-Tomoderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 2012; 185:612-619
25. Schleich FN, Seidel L, Sele J, et al. Exhaled nitric oxide thresholds associated with a sputum eosinophil count-3% in a cohort of unselected patients with asthma. Thorax 2010; 65:1039-1044
26. Schleich F, Manise M, Sele J, et al. Distribution of sputum cellular phenotype in a large asthma cohort: Predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 2013; 13:11
27. Black P, Blasi F, Jenkins C, et al. Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. Am J Respir Crit Care Med 2001; 164:536-541
28. Kraft M, Cassell GH, Pak J, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: Effect of clarithromycin. Chest 2002; 121:1782-1788
29. Johnston SL, Blasi F, Black PN, et al. The effect of telithromycin in acute exacerbations of asthma. N Engl J Med 2006; 354:1589-1600
30. Hodge S, Hodge G, Brozyna S, et al. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28:486-495
31. Hodge S, Hodge G, Jersmann H, et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:139-148
32. Kohri K, Ueki IF, Nadel JA. Neutrophil elastase induces mucin production by ligand-Dependent epidermal growth factor receptor activation. Am J Physiol Lung Cell Mol Physiol 2002; 283:L531-540
33. Gorrini M, Lupi A, Viglio S, et al. Inhibition of human neutrophil elastase by erythromycin and flurythromycin, two macrolide antibiotics. Am J Respir Cell Mol Biol 2001; 25:492-499
34. Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 2008; 177:148-155
35. Juncadella IJ, Kadl A, Sharma AK, et al. Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation. Nature 2013; 493:547-551
36. Braunstahl GJ. Chronic rhinosinusitis, nasal polyposis and asthma: The united airways concept reconsidered? Clin Exp Allergy 2011; 41:1341-1343
37. Videler WJ, Badia L, Harvey RJ, et al. Lack of efficacy of long-Term, low-Dose azithromycin in chronic rhinosinusitis: A randomized controlled trial. Allergy 2011; 66:1457-1468
38. Coeman M, Van Durme Y, Bauters F, et al. Neomacrolides in the treatment of patients with severe asthma and/or bronchiectasis: A retrospective observational study. Therap Adv Respir Dis 2011; 5:377-386
39. Shoji T, Yoshida S, Sakamoto H, et al. Anti-inflammatory effect of roxithromycin in patients with aspirin-intolerant asthma. Clin Exp Allergy 1999; 29:950-956
40. Sutherland ER, King TS, Icitovic N, et al. A trial of clarithromycin for the treatment of suboptimally controlled asthma. J Allergy Clin Immunol 2010; 126:747-753
41. Richeldi L, Ferrara G, Fabbri LM, et al. Macrolides for chronic asthma. Cochrane Database Syst Rev 2005; 4:CD002997
42. Strunk RC, Bacharier LB, Phillips BR, et al. Azithromycin or montelukast as inhaled corticosteroid-sparing agents in moderate-To-severe childhood asthma study. J Allergy Clin Immunol 2008; 122:1138-1144
43. Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 2003; 167:1655-1659
44. Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176:1062-1071
45. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360:973-984
46. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380:651-659
47. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: Standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99
48. Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax 2013; 68:322-329
49. Hahn DL, Grasmick M, Hetzel S, et al. Azithromycin for bronchial asthma in adults: An effectiveness trial. J Am Board Fam Med 2012; 25:442-459
50. Serisier D. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases. Lancet Respir Med 2013; 1:262-274
51. Malhotra-Kumar S, Lammens C, Coenen S, et al. Effect of azithromycin and clarithromycin therapy on pharyngeal carriage of macrolide-resistant streptococci in healthy volunteers: A randomised, double-blind, placebo-controlled study. Lancet 2007; 369:482-490
52. Ray WA, Murray KT, Hall K, et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012; 366:1881-1890
53. Svanström H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013; 368:1704-1712
54. Wenzel RP, Fowler AA, Edmond MB. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med 2012; 367:340-347
55. Gielen V, Johnston SL, Edwards MR. Azithromycin induces antiviral responses in bronchial epithelial cells. Eur Respir J 2010; 36:646-654